Cargando…

Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding

BACKGROUND: Growth differentiation factor‐15 (GDF‐15) is related to major bleeding when measured at initial presentation in patients with acute coronary syndromes (ACSs) treated with dual antiplatelet therapy. It is unknown whether follow‐up measurements provide additional information. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindholm, Daniel, Hagström, Emil, James, Stefan K., Becker, Richard C., Cannon, Christopher P., Himmelmann, Anders, Katus, Hugo A., Maurer, Gerald, López‐Sendón, José Luis, Steg, Philippe Gabriel, Storey, Robert F., Siegbahn, Agneta, Wallentin, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533037/ https://www.ncbi.nlm.nih.gov/pubmed/28411246 http://dx.doi.org/10.1161/JAHA.117.005580

Ejemplares similares

Interleukin‐18 in patients with acute coronary syndromes
por: Åkerblom, Axel, et al.
Publicado: (2019)

Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: Åkerblom, Axel, et al.
Publicado: (2019)

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
por: Ueland, Thor, et al.
Publicado: (2018)

Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study
por: Sumaya, Wael, et al.
Publicado: (2020)

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy
por: Sumaya, Wael, et al.
Publicado: (2018)

Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial
por: Batra, Gorav, et al.
Publicado: (2022)

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
por: Storey, Robert F., et al.
Publicado: (2014)

Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020)

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
por: Lindholm, Daniel, et al.
Publicado: (2014)

The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
por: Husted, Steen, et al.
Publicado: (2014)

Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial
por: Hjort, Marcus, et al.
Publicado: (2022)

GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
por: Wallentin, Lars, et al.
Publicado: (2013)

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
por: Andell, Pontus, et al.
Publicado: (2015)

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
por: Attelind, Sofia, et al.
Publicado: (2022)

Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome
por: Johansson, Åsa, et al.
Publicado: (2015)

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
por: Pol, Tymon, et al.
Publicado: (2021)

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan K, et al.
Publicado: (2011)

Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
por: Held, Claes, et al.
Publicado: (2017)

Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y(12) Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial
por: Franchi, Francesco, et al.
Publicado: (2019)

Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial
por: Gregersen, Ida, et al.
Publicado: (2020)

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study
por: Wallentin, Lars, et al.
Publicado: (2021)

Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials
por: Mahmoodi, Bakhtawar K., et al.
Publicado: (2021)

Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial
por: Bellavia, Andrea, et al.
Publicado: (2017)

Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease
por: Stewart, Ralph A. H., et al.
Publicado: (2017)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
por: Hijazi, Ziad, et al.
Publicado: (2020)

Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
por: Mahmoodi, Bakhtawar K., et al.
Publicado: (2021)

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
por: Magnani, Giulia, et al.
Publicado: (2021)

Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses
por: González-Pérez, Antonio, et al.
Publicado: (2016)

Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)
por: Siegbahn, Agneta, et al.
Publicado: (2023)

72-Year-old woman with effort angina >3 <12 months after acute myocardial infarction
por: López-Sendón, José
Publicado: (2019)

Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets
por: Edén, Desirée, et al.
Publicado: (2015)

Activation of β1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival
por: Åberg, Mikael, et al.
Publicado: (2020)

Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease
por: Stewart, Ralph A. H., et al.
Publicado: (2016)

Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
por: Yee, Megan K., et al.
Publicado: (2019)

Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome
por: Mälarstig, A, et al.
Publicado: (2008)

UX15-month-by-month
Publicado: (2003)

UX15-month-by-month
Publicado: (2004)

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
por: Varenhorst, Christoph, et al.
Publicado: (2009)

MircoRNA in Extracellular Vesicles from Patients with Pulmonary Arterial Hypertension Alters Endothelial Angiogenic Response
por: Khandagale, Avinash, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vg9fa2usmt3egr9jqut27j04g8